Keyuan Pharmaceutical announced that the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the rotigotin API approved and issued by the State Drug Administration. The approval conclusion was approval for registration; the results of the joint review and approval of the active ingredient were shown as “A” on the CDE original auxiliary package registration information platform and the formulation, which is valid for 5 years.

Keyuan Pharmaceutical announced that the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the rotigotin API approved and issued by the State Drug Administration. The approval conclusion was approval for registration; the results of the joint review and approval of the active ingredient were shown as “A” on the CDE original auxiliary package registration information platform and the formulation, which is valid for 5 years.